Completed PHASE2 INTERVENTIONAL 14-arm NCT02038907

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine (NOR-107)

A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuvanted With or Without Monophosphoryl Lipid A and Aluminum Hydroxide in Adults

Sponsor: Takeda

Conditions Healthy Volunteers Norovirus, Prevention

Interventions Hepatitis A Vaccine Norovirus Bivalent VLP Vaccine

Updated 8 times since 2017 Last updated: Aug 4, 2017 Started: Mar 28, 2014 Primary completion: Jun 19, 2015 Completion: Jun 19, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02038907, this PHASE2 trial focuses on Healthy Volunteers and Norovirus, Prevention and remains completed. Sponsored by Takeda, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Aug 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Aug 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edegem, Belgium
• Ghent, Belgium